Thinking about cancer or dealing with cancer risk can be scary or overwhelming, but we believe that receiving information and resources is comforting, empowering, and lifesaving.
Phase I results for a study that looked at treatment with talazoparib for advanced solid tumors (breast, ovarian, pancreatic, including people with BRCA mutations, were presented at the 2013 American Society of Clinical Oncology meeting. Results show that talazoparib is effective and well tolerated in patients with a BRCA mutation. This study looked at breast, ovarian, pancreatic, prostate and other cancers.
EMBRACA is a phase III clinical trial that is currently recruiting patients with advanced or metastatic breast cancer who have a BRCA mutation. Patients will receive either talazoparib or a physician’s choice of drug (Capecitabine, Eribulin, Gemcitabine or Vinorelbine) to see which treatment is more effective. To be eligible, patients cannot have received more than two prior chemotherapy regimens.